Global Trends in Antibiotic Expenditure: Analysis of Pharmaceutical Sales Data, 2013 to 2023
The Journal of Infectious Diseases · 14.11.2025 · 232 (5) · 1158-1167
DOI: 10.1093/infdis/jiaf346 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 03.07.2025. Verfasst von Arindam Nandi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Population Council, New York, New York. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Health Expenditures, Commerce. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Background
Human antibiotic consumption is a major contributing factor to antimicrobial resistance. Understanding the dynamics of the antibiotic market can help improve antibiotic stewardship efforts and encourage innovation.
Methods
We used quarterly pharmaceutical sales value and volume data from IQVIA MIDAS to estimate aggregate and per capita real annual spending (inflation adjusted) on antibiotics in 62 countries from 2013 to 2023, with unit values defined by the ratio of sales value and quantity. We evaluated trends by broad classes of antibiotics and country income groups and conducted multivariate regression analyses to identify associations with factors such as income and health spending.
Results
Between 2013 and 2023, aggregate and per capita real spending on antibiotics decreased from $49.61 billion to $30.68 billion and from $12.08 to $7.92, respectively. Real spending per unit of antibiotic, which is an indicator of price but not necessarily the final consumer price, also declined from $0.85 (2013) to $0.45 (2023). Spending decreased across country income groups and converged, driven by more rapid reductions in high-income countries as compared with other regions. In 2020, spending decreased sharply due to the COVID-19 pandemic, followed by a small rebound. In multivariate analysis, income, health spending, median age, and clean water access were associated positively with spending on antibiotics per 1000 people, while schooling attainment, availability of doctors, and higher state capacity were associated negatively.
Conclusions
Global spending on antibiotics declined and overall converged among countries from 2013 to 2023. More investment is necessary toward reducing antibiotic use and developing new effective antibiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Population Council, New York, New York.
- One Health Trust, Washington, DC.
- One Health Institute, University of Zürich, Switzerland.
- Spatial Epidemiology Lab, Université Libre de Bruxelles, Belgium.
- Department of Emergency Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
- GSK, Rixensart, Belgium.
ORCID-Profile: Arindam Nandi
Zitieren
APA
Nandi, A., Van Boeckel, T. P., Klein, E. Y., Denoel, P., Cipriano, M., Batheja, D., & Bloom, D. E. (2025). Global Trends in Antibiotic Expenditure: Analysis of Pharmaceutical Sales Data, 2013 to 2023. The Journal of Infectious Diseases, 232(5), 1158-1167. https://doi.org/10.1093/infdis/jiaf346
Vancouver
Nandi A, Van Boeckel TP, Klein EY, Denoel P, Cipriano M, Batheja D, et al. Global Trends in Antibiotic Expenditure: Analysis of Pharmaceutical Sales Data, 2013 to 2023. The Journal of Infectious Diseases. 2025;232(5):1158-1167. doi:10.1093/infdis/jiaf346
BibTeX
@article{Nandi2025,
author = {Nandi, Arindam and Van Boeckel, Thomas P and Klein, Eili Y and Denoel, Philippe and Cipriano, Mariateresa and Batheja, Deepshikha and Bloom, David E},
title = {Global Trends in Antibiotic Expenditure: Analysis of Pharmaceutical Sales Data, 2013 to 2023},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {232},
number = {5},
pages = {1158--1167},
doi = {10.1093/infdis/jiaf346}
}
EUVIMED